News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DeNovo Sciences Publishes On A First Of Its Kind CTC Technology


4/1/2014 9:37:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Plymouth, Michigan - DeNovo Sciences publishes “A novel microchannel-based device to capture and analyze circulating tumor cells (CTCs) of breast cancer”. DeNovo’s scientific team explored microfluidic capture techniques for isolating CTCs which has resulted in the development of proprietary technology to accomplish rare cell capture and analysis.

This newly developed technology is the first of its kind where CTCs are isolation and cell treatment processing, Immunochemistry, DNA FISH, mRNA FISH, and PCR, steps can be fully automated on DeNovo’s JETTA 400 instrument. One of the keys to monitoring breast metastatic disease is to understand how these rare cells migrate to other tissue or organs. With the ability to recover the bulk of these cells from a liquid or small tissue sample, it will provide the researchers the ability to better monitor CTC activity and migration patterns.

“With the commercial introduction of our JETTA 100 and 400 instruments later this year we will provide Cancer Research’s and Clinical Diagnostics the ability to easily isolate CTCs and monitor metastatic disease progression,” said Kalyan Handique, President of DeNovo Sciences. “We are looking forward to expanding and deepening our understanding of how these rare cells behave and migrate. It is our desire for this novel technology to be seen as a major leap forward in Cancer Diagnostics in the coming years.”

CTCs have been shown in many studies to be a possible biomarker for metastasis and may be instrumental for the spread of the disease. Key to monitoring breast metastatic disease is the understanding of how these rare cells migrate to other parts of a patient’s body. The ability to recover high percentages of these cells enable physicians to better track CTC activity and monitor the effectiveness of a specific cancer treatment.

The publication can be found on DeNovo’s web site or via Spandidos Publications the International Journal of Oncology link: http://www.spandidos-publications.com/10.3892/ijo.2014.2353.

About DeNovo Sciences, Inc.

DeNovo Sciences, Inc., a privately held Michigan based company, develops automated microfluidic systems for rare cell enrichment and single cell analysis. The Company is focused on detecting, analyzing and imaging Circulating Tumor Cells (CTC) as a companion to or in some cases a possible replacement to cancer biopsies. The Company’s sample preparation and imaging systems along with their reagent kits is an industry first. The JETTA 400 system performs all the required processing steps to isolate and preforms downstream single cell analysis to include Immunochemistry, DNA FISH, nRNA, and PCR while the VanGuard analysis the prepared slide automatically. This innovation allows the Healthcare Professional more time to focus on their patient’s therapeutic treatment and outcome.

Visit www.denovosciences.com to learn more.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES